HAART to Prevent HIV Transmission to Infants in Botswana


Principal Investigator:
Roger Shapiro, Assistant Professor in the Department of Immunology and Infectious Diseases

Immunology+Infectious Diseases Prime

Dates of Research:
September 1, 2005 — February 28, 2009


Highly active antiretroviral therapy (HAART) is rapidly becoming available in the developing world, but the safety and efficacy of different HAART regimens for preventing mother-to-child HIV transmission in a breastfeeding population has not been determined. A treatment, Trizivir, may be a simple, safe, and effective strategy to prevent mother-to-child transmission. This study will use 560 pregnant women in Botswana who intend to breastfeed and who will be divided into groups that will receive different treatments from 20-34 weeks of pregnancy to 6 months after giving birth. Women and infants in the program will be followed until the infant reaches 12 months of age. Analysis will provide a complete picture of the risks and benefits of each HAART regimen as well as other analysis that will address whether HAART started during pregnancy leads to infant prematurity and low birth weight. The Botswana government has given explicit support for this protocol to occur in four existing Botswana-Harvard AIDS Institute Partnership locations to help guide future policy decisions.